A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Clinical trial NCT01931839 · COMPLETED

Trial details

NCT number: NCT01931839
Sponsor: Vertex Pharmaceuticals Incorporated
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

Start date: 2013-10-01
Primary completion: 2016-04-01
Enrollment: 1164

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.